Hepatic myelopathy after transjugular intrahepatic portosystemic shunt:natural course,survival analysis,and treatment

Ren ShuYao; Chen Hui; Lu: Yong; Wang ZhengYu; Niu Jing; Yin ZhanXin; He ChuangYe; Guo WenGang; Han GuoHong

doi:10.3969/j.issn.1001-5256.2016.06.018

Issue 6

Jun. 2016

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2016 > 32(6): 1112-1117

PDF( 246 KB)

Hepatic myelopathy after transjugular intrahepatic portosystemic shunt:natural course,survival analysis,and treatment

DOI: 10.3969/j.issn.1001-5256.2016.06.018

Published Date: 2016-06-20

Abstract

Abstract

Objective To investigate the features of hepatic myelopathy(HM) after transjugular intrahepatic portosystemic shunt(TIPS).Methods A retrospective analysis was performed for a consecutive cohort of patients with cirrhotic portal hypertension who were successfully treated with TIPS in Department of Liver Disease and Digestive Interventional Radiology in Xijing Hospital of Digestive Diseases,Fourth Military Medical University,from 2005 to 2014 and then developed HM.Routine follow- up was performed for all patients at 1,3,and 6months after TIPS and every half a year subsequently.The time to disease progression was used to summarize the natural course of HM,the comparison of continuous data was made by independent samples t- test,the comparison of categorical date was made by chi- square test.The Kaplan- Meier method was used for survival analysis,and the Cox proportional hazards regression model was used to determine prognostic factors.Relief of symptoms in the lower limbs was analyzed to investigate the therapeutic effect.Results The time to HM progression from grade 1 to grades 2,3,and 4 was 4.0 months(range,1- 36 months),8.5 months(range,1- 44 months),and 18.8 months(range,5.4- 48.6 months),respectively.In HM patients,the 1-,3-,and 5- year cumulative survival rates were 84.19%,51.86%,and 45.21%,respectively.Age of HM onset(HR = 1.034,95% CI:1.003- 1.065) and recurrent ascites(HR = 3.869,95% Cl:1.623- 9.225) were independent prognostic factors in patients with HM.The patients who underwent liver transplantation had a significantly higher proportion of patients with relief of symptoms than those who did not undergo liver transplantation(χ2= 13.5,P = 0.003),while the effects of stent flow limitation and occlusion showed no significant differences(P > 0.05).Conclusion The course of HM consists of rapid progression stage and plateau stage,and HM patients after TIPS show good survival.At present,liver transplantation is an effective method to treat HM.
- liver cirrhosis,
- hypertension,
- portal,
- hepatic myelopathy

FullText(HTML)

References(12)

References

[1]BAJAJ JS.Liver capsule:hepatic encephalopathy[J].Hepatology,2015,62(3):955.

[2]TIBERI O,TOGNARELLI JM,COOK NA,et al.Diagnosing and treating hepatic encephalopathy[J].Br J Hosp Med(Lond),2015,76(11):646,648-652,654.

[3] ELLUL MA,GHOLKAR SA,CROSS TJ.Hepatic encephalopathy due to liver cirrhosis[J].BMJ,2015,351:h4187.

[4]CORDOBA J.New assessment of hepatic encephalopathy[J].J Hepatol,2011,54(5):1030-1040.

[5]LALEMAN W,SIMON-TALERO M,MALEUX G,et al.Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy:a multicenter survey on safety and efficacy[J].Hepatology,2013,57(6):2448-2457.

[6]MOORE KP,WONG F,GINES P,et al.The management of ascites in cirrhosis:report on the consensus conference of the International Ascites Club[J].Hepatology,2003,38(1):258-266.

[7]NARDONE R,HOLLER Y,STORTI M,et al.Spinal cord involvement in patients with cirrhosis[J].World J Gastroenterol,2014,20(10):2578-2585.

[8] KORI P,SAHU R,JAISWAL A,et al.Hepatic myelopathy:an unusual neurological complication of chronic liver disease presenting as quadriparesis[J].BMJ Case Rep,2013.pii:bcr2013-009078.

[9] PANICKER J,SINHA S,TALY A,et al.Hepatic myelopathy:a rare complication following extrahepatic portal vein occlusion and lienorenal shunt[J].Neurol India,2006,54(3):298-300.

[10]D'AMICO G,GARCIA-TSAO G,PAGLIARO L,et al.Natural history and prognostic indicators of survival in cirrhosis:a systematic review of 118 studies[J].J Hepatol,2006,44(1):217-231.

[11]ZHAO HW,LIU FQ,YUE ZD,et al.Clinical effects of transjugular interventional stent-shunt therapy in hepatic myelopathy after transjugular intrahepatic portosystemic shunt[J].Chin J Radiol,2013,47(3):239-244.(in Chinese)赵洪伟,刘福全,岳振东,等.经颈静脉途径介入干预经颈静脉肝内门体静脉分流术分流后肝性脊髓病的临床疗效[J].中华放射学杂志,2013,47(3):239-244.

[12]CALDWELL C,WERDIGER N,JAKAB S,et al.Use of model for end-stage liver disease exception points for early liver transplantation and successful reversal of hepatic myelopathy with a review of the literature[J].Liver Transpl,2010,16(7):818-826.

Relative Articles

[1]	Chenlu ZHAO, Suping MA, Dongfang SHANG, Sutong LIU, Xiaoyan LIU, Yuanyuan ZHENG, Wenxia ZHAO. Association of menopausal time and menopausal age with nonalcoholic fatty liver disease： An analysis based on a restricted cubic spline model[J]. Journal of Clinical Hepatology, 2025, 41(2): 247-253. doi: 10.12449/JCH250209
[2]	Jiang DENG, Zhiyi HAN, Cailan XIAO, Yating SUN, Yajun JI, Li AO, Yonghong ZHANG, Xiaolan LU. Prevalence rate of non-obese fatty liver disease and related influencing factors[J]. Journal of Clinical Hepatology, 2021, 37(11): 2600-2604. doi: 10.3969/j.issn.1001-5256.2021.11.022
[3]	Wenqian XU, Yaoqi WU, Jinyuan ZHANG, Tianchuang YANG, Heguo LI, Min GUO. Mechanism of estrogen against liver fibrosis in postmenopausal women with chronic liver disease[J]. Journal of Clinical Hepatology, 2021, 37(10): 2425-2428. doi: 10.3969/j.issn.1001-5256.2021.10.035
[4]	Yao ChengZi, Feng Gong, Yu WenSi, Du Huan, Mi Man. Risk factors for the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(2): 433-436. doi: 10.3969/j.issn.1001-5256.2020.02.044
[5]	Ren DanDan, Liu Na, Zhou LuLu, Zhang Nan, Li ChunXia, Dong Bing, Xu GuangHua. Risk factors for hepatitis B virus-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(7): 1634-1638. doi: 10.3969/j.issn.1001-5256.2020.07.041
[6]	Shu YunRan, Li JunQi, Liu Qiong. Epidemiology of nonalcoholic fatty liver disease and related risk factors[J]. Journal of Clinical Hepatology, 2019, 35(9): 2085-2090. doi: 10.3969/j.issn.1001-5256.2019.09.045
[7]	Sun MiaoMiao, Cao LiYing, Sun WeiDong, Liu XiNing, Cui HaoZhe, Liang MingYang, Wei YaoChen, Wang WanChao, Liu SiQing. Association of serum high-density lipoprotein cholesterol with new-onset cholelithiasis[J]. Journal of Clinical Hepatology, 2019, 35(8): 1745-1750. doi: 10.3969/j.issn.1001-5256.2019.08.019
[8]	Feng Gong, Mi Man, Li XuePing, He Na, Chen ZiJun, Niu ChunYan. The economic burden and risk factors in inflammatory bowel disease with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2018, 34(12): 2702-2706. doi: 10.3969/j.issn.1001-5256.2018.12.042
[9]	Chen QinQin, Liang CanCan, Yang LiJun, Meng Qing, Ding YongNian. A clinical analysis of Uygur patients with acute ischemic cerebral infarction complicated by nonalcoholic fatty liver disease in Urumqi, China[J]. Journal of Clinical Hepatology, 2018, 34(6): 1259-1263. doi: 10.3969/j.issn.1001-5256.2018.06.025
[10]	Zhao HongXin, Yan Rong, Niu ChunYan, Zhou YongLi, Wang Jia, Cao RuiQi. Prevalence and associated risk factors for obesity and nonalcoholic fatty liver disease in adolescents in Xi′an, Shaanxi province, China[J]. Journal of Clinical Hepatology, 2015, 31(8): 1248-1251. doi: 10.3969/j.issn.1001-5256.2015.08.016
[11]	Cai Wen, Dong ZhengHui, Wang ShuXia, Yang XiaoPing, Yao Hua. Analysis of correlation between serum 25- hydroxyvitamin D level and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2015, 31(7): 1059-1062. doi: 10.3969/j.issn.1001-5256.2015.07.015
[12]	Qiao LiNa, Dai GuangRong, Zhang Jin, Shen Ni. An epidemiological survey of prevalence and risk factors for fatty liver disease in adults residing in Yan'an,China[J]. Journal of Clinical Hepatology, 2015, 31(1): 82-87. doi: 10.3969/j.issn.1001-5256.2015.01.018
[13]	Lin Wei, Si JianLin, Zhang Jian, Maimaitijiang·Wubuliaishan, Hu ZhiMing, Li DongZeng, Geng Nan. Pegylated interferon alpha-2a combined with ribavirin for chronic hepatitis C: a clinical analysis of 160 patients of Uygur nationality or Han nationality[J]. Journal of Clinical Hepatology, 2015, 31(11): 1831-1836. doi: 10.3969/j.issn.1001-5256.2015.11.015
[14]	Zhang Jian. Correlation between malnutrition and prognosis of hepatitis A in Uygur children[J]. Journal of Clinical Hepatology, 2015, 31(8): 1235-1237. doi: 10.3969/j.issn.1001-5256.2015.08.013
[15]	Wu XiaoQing, Wan Hong. Causes of liver failure and impact analysis of prognostic risk factors[J]. Journal of Clinical Hepatology, 2013, 29(4): 294-296+304.
[16]	Chen YongFang, Wu ZhanJun. Pathogenesis and risk factors of cholesterol gallstones in patients with non- alcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2013, 29(12): 952-955. doi: 10.3969/j.issn.1001-5256.2013.12.021
[17]	Wu Tao, Yin ShouYi, Wang HongZhang, Zhang Hong, Jia Wei, Ji Guang. The clinical features and risk factors of patient with metabolic syndrome combined with non-alcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2011, 27(10): 1036-1040.
[18]	Zhang YiNing, Du HongWei, Liu YanJun, Wang ChaoXia. The diagnosis and risk factors for evaluation of nonalcoholic fatty liver disease in children and adolescents[J]. Journal of Clinical Hepatology, 2011, 27(7): 690-693.
[19]	Wan Hong, Li Ling, Tang YanPing. study on fatty liver prevalence in the government officers in Lanzhou area[J]. Journal of Clinical Hepatology, 2008, 24(4): 261-262.
[20]	Chen MingWei, Yang MingGong, Wang YouMin, Wang ZhangJiang, Pan TianRong, Hu HongLin, Sun HaiYan. Risk factors analysis on nonalcoholic steatohepatitis in patients with type 2 diabetes[J]. Journal of Clinical Hepatology, 2004, 20(1): 44-45.

Supplements(0)

Cited By

Cited by

Periodical cited type(2)

1.	廖雪姣，张丽娜，李轩，董京科，黄国仪. 绝经后女性非酒精性脂肪性肝病患者性激素水平与胰岛素抵抗肝酶学异常的关系. 山西医药杂志. 2019(14): 1658-1659 .
2.	丁智勇，卜乐，鲁鸿燕，饶正轩. 非酒精性脂肪性肝病患者血清维生素A水平、肝脏脂肪含量与胰岛素抵抗的相关性分析. 临床肝胆病杂志. 2017(12): 2361-2365 . 本站查看

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (436) PDF downloads(173)

Hepatic myelopathy after transjugular intrahepatic portosystemic shunt:natural course,survival analysis,and treatment

DOI: 10.3969/j.issn.1001-5256.2016.06.018